(Albany, USA) DelveInsight’s “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Neuroblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Neuroblastoma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Neuroblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Neuroblastoma market.
Request for a Free Sample Report @ Neuroblastoma Market Forecast
Some facts of the Neuroblastoma Market Report are:
- According to DelveInsight, Neuroblastoma market size is expected to grow at a decent CAGR by 2032.
- Leading Neuroblastoma companies working in the market are Aptorum, Athenex, Eli Lilly, Clarity Pharmaceuticals, Y-mAbs Therapeutics Inc, Novartis AG, Bristol-Myers Squibb, F. Hoffmann-La Roche, EUSA Pharma, United Therapeutics, Pfizer, APEIRON Biologics AG, United Therapeutics, AstraZeneca Plc, Baxter International Inc, Cellectar Biosciences, Bayer, Sanofi, Merck and Others.
- Key Neuroblastoma Therapies expected to launch in the market are UNITUXIN (dinutuximab), QARZIBA (dinutuximab beta), Omburtamab, 67Cu-SARTATE, Abemaciclib, Ribociclib, KUR-501, SACT-1, SARTATE, and others.
- In March 2023, Y-mAbs Therapeutics announced a study on Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- In May 2023, Ascentage Pharma Group Inc. announced an open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.
Neuroblastoma Overview
Neuroblastoma is a rare form of cancer that primarily affects infants and young children, arising from immature nerve cells found in different parts of the body, most commonly in the adrenal glands. It is characterized by the uncontrolled growth of neuroblast cells, leading to the formation of tumors. Neuroblastoma can manifest in various locations, including the abdomen, chest, neck, and pelvis. Neuroblastoma Symptoms may vary depending on the tumor’s size and location, but commonly include abdominal pain, swollen abdomen, bone pain, fatigue, and weight loss. Treatment options include surgery, chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation, depending on the stage and risk classification of the disease.
Learn more about Neuroblastoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market
Neuroblastoma Market
The Neuroblastoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Neuroblastoma market trends by analyzing the impact of current Neuroblastoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Neuroblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neuroblastoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Neuroblastoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Neuroblastoma Epidemiology
The Neuroblastoma epidemiology section provides insights into the historical and current Neuroblastoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Neuroblastoma market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Neuroblastoma Epidemiology @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market
Neuroblastoma Drugs Uptake
This section focuses on the uptake rate of the potential Neuroblastoma drugs recently launched in the Neuroblastoma market or expected to be launched in 2019-2032. The analysis covers the Neuroblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Neuroblastoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Neuroblastoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Neuroblastoma Pipeline Development Activities
The Neuroblastoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Neuroblastoma key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Neuroblastoma pipeline development activities @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market
Neuroblastoma Therapeutics Assessment
Major key companies are working proactively in the Neuroblastoma Therapeutics market to develop novel therapies which will drive the Neuroblastoma treatment markets in the upcoming years are Aptorum, Athenex, Eli Lilly, Clarity Pharmaceuticals, Y-mAbs Therapeutics Inc, Novartis AG, Bristol-Myers Squibb, F. Hoffmann-La Roche, EUSA Pharma, United Therapeutics, Pfizer, APEIRON Biologics AG, United Therapeutics, AstraZeneca Plc, Baxter International Inc, Cellectar Biosciences, Bayer, Sanofi, Merck and Others.
Learn more about the emerging Neuroblastoma therapies & key companies @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market
Neuroblastoma Report Key Insights
1. Neuroblastoma Patient Population
2. Neuroblastoma Market Size and Trends
3. Key Cross Competition in the Neuroblastoma Market
4. Neuroblastoma Market Dynamics (Key Drivers and Barriers)
5. Neuroblastoma Market Opportunities
6. Neuroblastoma Therapeutic Approaches
7. Neuroblastoma Pipeline Analysis
8. Neuroblastoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Neuroblastoma Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Neuroblastoma Competitive Intelligence Analysis
4. Neuroblastoma Market Overview at a Glance
5. Neuroblastoma Disease Background and Overview
6. Neuroblastoma Patient Journey
7. Neuroblastoma Epidemiology and Patient Population
8. Neuroblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuroblastoma Unmet Needs
10. Key Endpoints of Neuroblastoma Treatment
11. Neuroblastoma Marketed Products
12. Neuroblastoma Emerging Therapies
13. Neuroblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Neuroblastoma Market Outlook (7 major markets)
16. Neuroblastoma Access and Reimbursement Overview
17. KOL Views on the Neuroblastoma Market
18. Neuroblastoma Market Drivers
19. Neuroblastoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting